Voya Investment Management LLC lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 842.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 90,011 shares of the medical research company’s stock after acquiring an additional 80,456 shares during the quarter. Voya Investment Management LLC’s holdings in Charles River Laboratories International were worth $26,554,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Edgestream Partners L.P. purchased a new stake in shares of Charles River Laboratories International during the third quarter valued at approximately $1,443,000. Teachers Retirement System of The State of Kentucky lifted its holdings in Charles River Laboratories International by 319.7% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 16,814 shares of the medical research company’s stock worth $4,960,000 after acquiring an additional 12,808 shares during the period. HighTower Advisors LLC boosted its position in Charles River Laboratories International by 1,001.9% in the third quarter. HighTower Advisors LLC now owns 41,661 shares of the medical research company’s stock worth $12,290,000 after purchasing an additional 37,880 shares during the last quarter. Intech Investment Management LLC purchased a new position in Charles River Laboratories International in the third quarter worth $4,488,000. Finally, Bessemer Group Inc. boosted its position in Charles River Laboratories International by 1.6% in the third quarter. Bessemer Group Inc. now owns 23,314 shares of the medical research company’s stock worth $6,334,000 after purchasing an additional 362 shares during the last quarter. 98.91% of the stock is owned by institutional investors.
Insider Activity
In other Charles River Laboratories International news, Director James C. Foster sold 24,042 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at $11,058,600. This trade represents a 43.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,655,578.87. The trade was a 30.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 60,740 shares of company stock worth $19,528,128. Insiders own 1.30% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on CRL shares. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. Jefferies Financial Group lifted their target price on Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. UBS Group boosted their price target on shares of Charles River Laboratories International from $357.00 to $387.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Finally, Morgan Stanley increased their price target on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $311.67.
Get Our Latest Stock Report on CRL
Charles River Laboratories International Stock Down 4.2%
Shares of NYSE CRL opened at $314.29 on Friday. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $379.63. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.12. The business’s fifty day moving average price is $316.09 and its 200-day moving average price is $231.19. The stock has a market capitalization of $15.06 billion, a PE ratio of 345.37, a P/E/G ratio of 3.03 and a beta of 1.36.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The company had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. During the same quarter last year, the firm posted $2.43 EPS. The firm’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.45 EPS for the current year.
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
